The Pancreatic Cancer Action Network (PanCAN) offers an adaptive platform for clinical research, known as Precision Promise, plans on launching a clinical trial at 14 Clinical Trial Consortium sites across American starting in the Fall of 2019 through early 2020. An adaptive clinical trial, the sponsor will allow multiple experimental treatment options to be tested at the same time.
What is an Adaptive Clinical Trial?
Adaptive clinical trials are used to evaluate a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and modifying parameters of the trial protocol in accord with those observations. The adaption process generally continues throughout the trial, as prescribed in the trial protocol. Modifications may include dosage, sample size, drug undergoing trial, patient selection criteria and “cocktail mix.” Sometimes the trials become an ongoing process that regularly adds and drops therapies and patient groups as more information is generated. The trial protocol is getting before the trial begins; the protocol pre-specified the adaption schedule and processes.
Victoria Manax, MD Chief Medical Officer, PanCAN notes that “Adaptive platform clinical trials can be a faster, less expensive, more efficient way to learn which treatments do and do not work for patients.”
PanCAN’s own adaptive platform clinical trial is called Precision Promise. The first adaptive clinical trial platform for pancreatic cancer patients in the world and the Pancreatic Cancer Action Network’s groundbreaking initiative to dramatically improve patient outcomes and advanced the non-profit group’s goal to double survival by 2020. The platform was designed by a nationwide team of leading clinicians, researchers and diagnostic and drug developers, Precision Promise will continuously bring new treatment options to patients and transform the future.
Clinical Trial Consortium Sites
PanCAN touts its has designed an unprecedented model of cooperation involving steering committees and sub-committees of renowned experts nationwide. The effort involves their Clinical Trial Consortium sites selected through a competitive peer-review process. See the link for a map of the sites.
Founding Precision Promise members include industry participants: Celgene, AstraZeneca, Janssen Oncology, Bristol-Myers Squibb and Halozyme.
What is PanCAN?
The Pancreatic Cancer Action Network (PanCAN) is dedicated to fighting the world’s toughest chancer. A non-profit, they attack pancreatic cancer on all fronts: research, clinical initiatives, patient services, and advocacy. Formed in 1999 the link offers a video history. The network was founded by Pamela Acosta Marquardt, Paula Kim, and Terry Lierman.
Since 2003, PanCAN, working in partnership with donors, has invested about $104 million including their competitive Research Grants Program and various scientific and clinical initiatives.
Pancreatic Cancer: The Danger
According to the American Cancer Society, about 56,770 people will be diagnosed with pancreatic cancer. About 45,750 will die of pancreatic cancer this year. Pancreatic cancer accounts for about 3% of all cancers in the U.S and about 7% of all cancer deaths.
Call to Action: Do you or a family member have a pancreatic cancer diagnosis? Contact PanCAN to identify options.